With Juliet Dirba, Kristen Foster, Stephen Hash
The standard for patent eligible subject matter under 35 U.S.C. § 101 remains amorphous despite the Federal Circuit's recent decision in Classen Immunotherapies, Inc. v. Biogen IDEC (Fed. Cir. No. 2006-1634,-1649) (August 31, 2011).